Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 38

1.

Rho-kinase regulates energy balance by targeting hypothalamic leptin receptor signaling.

Huang H, Kong D, Byun KH, Ye C, Koda S, Lee DH, Oh BC, Lee SW, Lee B, Zabolotny JM, Kim MS, Bjørbæk C, Lowell BB, Kim YB.

Nat Neurosci. 2012 Oct;15(10):1391-8. doi: 10.1038/nn.3207.

2.

Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis.

Mascarenhas J, Hoffman R.

Clin Cancer Res. 2012 Jun 1;18(11):3008-14. doi: 10.1158/1078-0432.CCR-11-3145.

3.

Challenges facing JAK inhibitor therapy for myeloproliferative neoplasms.

Tefferi A.

N Engl J Med. 2012 Mar 1;366(9):844-6. doi: 10.1056/NEJMe1115119. No abstract available.

PMID:
22375977
4.

JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths.

Tefferi A.

Blood. 2012 Mar 22;119(12):2721-30. doi: 10.1182/blood-2011-11-395228.

5.

Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.

Tefferi A, Pardanani A.

Mayo Clin Proc. 2011 Dec;86(12):1188-91. doi: 10.4065/mcp.2011.0518.

6.

Long-term outcome of treatment with ruxolitinib in myelofibrosis.

Tefferi A, Litzow MR, Pardanani A.

N Engl J Med. 2011 Oct 13;365(15):1455-7. doi: 10.1056/NEJMc1109555. No abstract available.

7.

JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective.

Tefferi A, Pardanani A.

Blood Rev. 2011 Sep;25(5):229-37. doi: 10.1016/j.blre.2011.06.002. Review.

PMID:
21742423
8.

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies.

Hart S, Goh KC, Novotny-Diermayr V, Hu CY, Hentze H, Tan YC, Madan B, Amalini C, Loh YK, Ong LC, William AD, Lee A, Poulsen A, Jayaraman R, Ong KH, Ethirajulu K, Dymock BW, Wood JW.

Leukemia. 2011 Nov;25(11):1751-9. doi: 10.1038/leu.2011.148.

PMID:
21691275
9.

Intrinsic and extrinsic effects of mafG deficiency on hematopoietic recovery following bone marrow transplant.

Li XM, Hu Z, Zafar AB, Jorgensen ML, Bungert J, Slayton W.

Exp Hematol. 2010 Dec;38(12):1251-60. doi: 10.1016/j.exphem.2010.08.005.

PMID:
20813153
10.

Critical role of Src-Syk-PLC{gamma}2 signaling in megakaryocyte migration and thrombopoiesis.

Mazharian A, Thomas SG, Dhanjal TS, Buckley CD, Watson SP.

Blood. 2010 Aug 5;116(5):793-800. doi: 10.1182/blood-2010-03-275990.

11.

The Rho exchange factor Arhgef1 mediates the effects of angiotensin II on vascular tone and blood pressure.

Guilluy C, Brégeon J, Toumaniantz G, Rolli-Derkinderen M, Retailleau K, Loufrani L, Henrion D, Scalbert E, Bril A, Torres RM, Offermanns S, Pacaud P, Loirand G.

Nat Med. 2010 Feb;16(2):183-90. doi: 10.1038/nm.2079.

PMID:
20098430
12.

Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity.

Neria F, Castilla MA, Sanchez RF, Gonzalez Pacheco FR, Deudero JJ, Calabia O, Tejedor A, Manzarbeitia F, Ortiz A, Caramelo C.

Kidney Int. 2009 Jan;75(2):227-34. doi: 10.1038/ki.2008.487.

13.

Regulation of myeloproliferation and M2 macrophage programming in mice by Lyn/Hck, SHIP, and Stat5.

Xiao W, Hong H, Kawakami Y, Lowell CA, Kawakami T.

J Clin Invest. 2008 Mar;118(3):924-34. doi: 10.1172/JCI34013.

14.
15.

A functional Jak2 tyrosine kinase domain is essential for mouse development.

Frenzel K, Wallace TA, McDoom I, Xiao HD, Capecchi MR, Bernstein KE, Sayeski PP.

Exp Cell Res. 2006 Sep 10;312(15):2735-44.

PMID:
16887119
16.

The role of Janus kinases in haemopoiesis and haematological malignancy.

Khwaja A.

Br J Haematol. 2006 Aug;134(4):366-84. Review.

PMID:
16822289
17.

Lyn kinase promotes erythroblast expansion and late-stage development.

Karur VG, Lowell CA, Besmer P, Agosti V, Wojchowski DM.

Blood. 2006 Sep 1;108(5):1524-32.

18.

Increased megakaryocytopoiesis in Lyn-deficient mice.

Lannutti BJ, Minear J, Blake N, Drachman JG.

Oncogene. 2006 Jun 1;25(23):3316-24.

PMID:
16418722
19.

Identification of an acquired JAK2 mutation in polycythemia vera.

Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, Zhao ZJ.

J Biol Chem. 2005 Jun 17;280(24):22788-92.

20.

A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC.

N Engl J Med. 2005 Apr 28;352(17):1779-90.

Items per page

Supplemental Content

Support Center